SA JOURNAL OF DIABETES & VASCULAR DISEASE
VOLUME 13 NUMBER 2 • DECEMBER 2016
17. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic
volume determinations: echocardiographic-angiopgraphic correlations in the
presence of absence in the presence of absence of synergy.
Am J Cardiol
18. Lu B, Song X, Dong X, Yang Y, Zhang Z, Wen J,
. High prevalence of chronic
kidney disease in population-based patients diagnosed with type 2 diabetes in
J Diabetes Complic
19. Lemley KV. Diabetes and chronic kidney disease: lessons from the Pima Indians.
20. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular
complications of diabetes. Pharmacol Res 2007; 55(6): 498–510.
21. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic
abnormalities – the role of insulin resistance and the sympathoadrenal system.
N Engl J Med
22. Ritz E. Metabolic syndrome and kidney disease. Blood Purif 2008; 26(1):
23. Paravivini TM, Touyz RM. NAD (P) H oxidase, reactive oxygen species, and
hypertension: clinical implications and therapeutic possibilities.
(Suppl. 2): S170–S180.
24. Kis E, Cseprekal O, Horvath Z, Katona G, Fekete BC,Hrapka L,
pressure velocity in end-stage renal disease: influence of age and body
25. Minutolo R, Borrelli S, Chiodini P, Scigliano R, Bellizzi V, Cianciaruso B,
Effects of age on hypertensive status in patients with chronic kidney disease.
26. Laurent S, Boutouyrie P. Arterial Stiffness: a ne surrogate end point for
(Suppl. 12): S45–S50.
27. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F, for the MMKD study group.
Uric acid as a risk factor for progression of non diabetic chronic kidney disease?
The Mild to Moderate Kidney Disease (MMKD) Study.
28. Nardi E, Cottone S, Mule G, Palermo A, Cusiman P, Cerasola G. Influence of
chronic renal insufficiency on left ventricular diastolic function in hypertensives
without left ventricular hypertrophy.
29. Agaba El. Characteristics of type 2 diabetics presenting with end-stage renal
disease at the Jos University Hospital, Nigeria.
West Afr J Med
30. Alebiosu CO, Odusan O, Familoni OB, Juiyesimi AE. Cardiovascular risk factors
in type 2 diabetic Nigerians with clinical diabetic nephropathy.
Cardiovasc J S
31. Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular disease and type 2
diabetes mellitus: Procceeding with caution at a dangerous intersection.
32. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid,
left ventricular mass index and risk of cardiovascular disease in essential
33. Ha SK, Park HS, Kim SJ, Park CH, Kim DS, Kim HS. Prevalence and patterns of
left ventricular hypertrophy in patients with predialysis chronic renal failure.
Korean Med Sci
34. Aje A, Adedeyi AA, Oladapo OO, Dada A, Ogah US, Ojji DB, Falase AD.
Left ventricular patterns in newly presenting Nigerian hypertensives: An
BMC Cardiovasc Disorders
35. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E,
. Serum uric
acid and target organ damage in primary hypertension.
36. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary
Transforming Growth Factor beta and the progression of chronic kidney disease.
Am J Nephrol
37. Choncol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS,
Relationship of uric acid with progression of kidney disease.
Am J Kidney Dis
38. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzoli,
. A role for
uric acid in the progression of renal disease.
J Am Soc Nephrol
Dyna Indapamide SR.
Each sustained release tablet contains 1,5 mg indapamide. Reg. No.: RSA S3
A42/7.1/0790. NAM NS2 12/7.1/0138. For full prescribing information, refer to the package insert approved
by the Medicines Control Council, 25 November 2011.
Weidmann P. Metabolic profile of indapamide
sustained-release in patients with hypertension. Drug Safety 2001;24(15):1155-1165.
– Accessed 06/06/2016.
CUSTOMER CARE LINE
0860 PHARMA (742 762)www.pharmadynamics.co.za
A Lupin Group Company
he effects of caffeine versus maltodextrin during exercise were
observed in patients with type 2 diabetes. Researchers examined
the effects on blood pressure (BP), heart rate (HR) and blood glucose
(BG) levels associated with the intake of caffeine in comparison
to maltodextrin (CHO) during prolonged periods of low-intensity
exercise in patients with type 2 diabetes.
Researchers conducted a pilot study on eight individuals with
type 2 diabetes who were aged 55 ± 10 years. The participants
either received 1 g/kg of CHO or 1.5 mg/kg of caffeine before
undergoing exercise. They then exercised for 40 minutes, executed
at 40% HR reserve, and recovered for 10 minutes.
Their BP and exertion, assessed by the Borg scale, were checked
every two minute, and their BG levels were checked every 10
minutes. The ANOVA test was used for statistical analysis, and a
-value < 0.05 indicated statistically significant results.
Neither of the treatments produced significant changes in
BP and HR. However, 1.5 mg/kg caffeine significantly reduced
BG levels by 75 mg/dl (65% CI;
< 0.05) as opposed to 1 g/kg
maltodextrin, which produced no significant change in BG levels
during the 40-minute period of exercise.
Da Silva LA, De Freitas L, Medeiros TE, Osiecki R, Garcia Michel R, Snak AL,
. Caffeine modifies blood glucose availability during prolonged low-intensity
exercise in individuals with type-2 diabetes.
Colomb Med (Cali)
(2):72-76. eCollection 2014 Apr. PubMed PMID: 25100892.
During prolonged low-intensity exercise,
caffeine alters blood glucose levels